Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 17:20:100495.
doi: 10.1016/j.ymgmr.2019.100495. eCollection 2019 Sep.

Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling

Affiliations

Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling

Li Ou et al. Mol Genet Metab Rep. .

Abstract

Gangliosidoses, including GM1-gangliosidosis and GM2-gangliosidosis (Tay-Sachs disease and Sandhoff disease), are lysosomal disorders resulting from enzyme deficiencies and accumulation of gangliosides. Phenotypes of gangliosidoses range from infantile, late-infantile, juvenile, and to the adult form. The genotype-phenotype correlation is essential for prognosis and clinical care planning for patients with a gangliosidosis condition. Previously, we have developed a method to establish the genotype-phenotype correlation of another lysosomal disease, mucopolysaccharidosis type I, with in silico tools. This same method was applied to analyze the genotype and phenotype of 38 patients diagnosed with a gangliosidosis disease in the United States. Out of 40 mutations identified, 3 were novel, including p.Tyr192His and p.Phe556Ser of the GLB1 gene and p.Gly461Val of the HEXA gene. Furthermore, the mutant protein structure of all missense mutations was constructed by homology modeling. A systemic structural analysis of these models revealed the specific mechanisms of how each mutation may lead to the disease. In summary, the method developed in this study holds promise as a tool that can be broadly applicable to other lysosomal diseases and monogenic diseases.

Keywords: Disease subtype; Gangliosidosis; Genotype-phenotype correlation; In silico; Lysosomal disorder.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Close-up view of superimposed structure of native and mutant residues. The main protein core is shown in gray color while the wild-type and mutant residues are shown in red and green color, respectively. The following mutants were shown: p.Arg170Trp, p.Gly123Arg, p.Leu155Arg and p.Tyr270Asp. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
Predicting disease subtypes based on mutations in autosomal recessive diseases. A general protocol for predicting disease subtypes of autosomal recessive diseases was proposed.

Similar articles

Cited by

References

    1. Sarafoglou K., Hoffmann G.F., Roth K.S. McGraw-Hill Company; New York: 2009. Pediatric Endocrinology and Inborn Errors of Metabolism; pp. 738–739. (& 744–745)
    1. Callahan J.W. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein. Biochim. Biophys. Acta. 1999;1455:85–103. - PubMed
    1. Jarnes Utz J.R., Kim S., King K., Ziegler R., Schema L., Redtree E.S., Whitley C.B. Infantile gangliosidoses: mapping a timeline of clinical changes. Mol. Genet. Metab. 2017;121(2):170–179. - PMC - PubMed
    1. Regier D.S., Proia R.L., D'Azzo A., Tifft C.J. The GM1 and GM2 gangliosidoses: natural history and Progress toward therapy. Pediatr. Endocrinol. Rev. 2016 Jun;13(Suppl. 1):663–673. - PMC - PubMed
    1. Maegawa G.H., Tropak M., Buttner J., Stockley T., Kok F., Clarke J.T., Mahuran D.J. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 2007 Mar 23;282(12):9150–9161. - PMC - PubMed

LinkOut - more resources